Lexicon Pharmaceuticals Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) Transcript

Sep 21, 2021 / 02:45PM GMT
Leland Gershell - Oppenheimer & Co. Inc. - Analyst

Good morning, everyone. Welcome to another session here at the second day of Oppenheimer's Virtual Fall Healthcare Summit. We are delighted to have with us Lexicon Pharmaceuticals. On behalf of Lexicon, we'll have the Company's CEO, Lonnel Coats, who will be walking through a presentation on the Company, and we will also have some time for questions at the end. If you have any questions you would like to submit, please do through -- do so through the Zoom chat function and I'll do my best to ask on your behalf.

And with that, I'll turn the microphone over to Lonnel.

Lonnel Coats - Lexicon Pharmaceuticals, Inc. - CEO & Director

Leland, thank you for your warm introduction and having us at this conference today. Let me start off by saying that Lexicon is making great progress and we look forward to sharing that progress with you today. But before I get started, I want to say that we will be making forward-looking statements today that are subject to risks and uncertainties. Certainly those risks

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot